NCIt definition : A fully human IgG1 monoclonal antibody directed against human vascular endothelial
growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic
activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1,
which may prevent the activation of downstream signaling pathways and so inhibit tumor
angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor
cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor
angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2
signaling.;
UNII : T7H0B1R64U;
CAS number : 1024603-92-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1024603-92-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;